ARCHIVES

Blue Cross, Broder Skirmish On Coverage Of Group C Drugs

This article is from The Cancer Letter archive.

Vol. 15 No. 42 | November 3, 1989

Download PDF Visit The Full Archive

Related Articles

340B Drug Discount Program: HRSA Defends Orphan Drug Rule

June 20, 2014

NIH Should Review CRADA Pricing, Wyden Write to Shalala

February 5, 1993

Also Kevin Cullen named director, Univ. of Maryland Greenebaum Cancer Center.

November 28, 2003

In Brief: Three More Comprehensive Centers May Be Names; Hawaii, Cleveland, Ohio State Lead List of 10

May 9, 1975

Paul Marks To Retire As President, CEO Of Memorial Sloan-Kettering Cancer Center

December 11, 1998

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008